<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nicoletti P</submitter><funding>NIA NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIMH NIH HHS</funding><funding>NHGRI NIH HHS</funding><funding>National Institute for Health Research (NIHR)</funding><funding>NCI NIH HHS</funding><pagination>454-466</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9974860</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>164(3)</volume><pubmed_abstract>&lt;h4>Background &amp; aims&lt;/h4>Drug-induced liver injury (DILI) due to amoxicillin-clavulanate (AC) has been associated with HLA-A∗02:01, HLA-DRB1∗15:01, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC-DILI and to construct a genetic risk score (GRS).&lt;h4>Methods&lt;/h4>Transcriptome-wide association study and genome-wide association study analyses were performed on 444 AC-DILI cases and 10,397 population-based controls of European descent. Associations were confirmed in a validation cohort (n = 133 cases and 17,836 population-based controls). Discovery and validation AC-DILI cases were also compared with 1358 and 403 non-AC-DILI cases.&lt;h4>Results&lt;/h4>Transcriptome-wide association study revealed a significant association of AC-DILI risk </pubmed_abstract><journal>Gastroenterology</journal><pubmed_title>Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.</pubmed_title><pmcid>PMC9974860</pmcid><funding_grant_id>U01 HG004603</funding_grant_id><funding_grant_id>U01 DK065201</funding_grant_id><funding_grant_id>U01 HG007417</funding_grant_id><funding_grant_id>U01 HG004424</funding_grant_id><funding_grant_id>U01 AG006781</funding_grant_id><funding_grant_id>U01 CA155309</funding_grant_id><funding_grant_id>UL1 RR025747</funding_grant_id><funding_grant_id>U01 DK065184</funding_grant_id><funding_grant_id>UL1 RR025761</funding_grant_id><funding_grant_id>RC2 MH089964</funding_grant_id><funding_grant_id>U01 HG004608</funding_grant_id><funding_grant_id>R01 MH084098</funding_grant_id><funding_grant_id>U01 HG004438</funding_grant_id><funding_grant_id>U01 DK065211</funding_grant_id><funding_grant_id>U01 DK083023</funding_grant_id><funding_grant_id>U01 DK065176</funding_grant_id><funding_grant_id>U01 DK083020</funding_grant_id><funding_grant_id>U01 DK083027</funding_grant_id><funding_grant_id>U01 DK100928</funding_grant_id><funding_grant_id>U01 DK082992</funding_grant_id><funding_grant_id>U24 DK065176</funding_grant_id><funding_grant_id>BRC-1215-20003</funding_grant_id><funding_grant_id>U01 DK065238</funding_grant_id><funding_grant_id>UL1 RR024986</funding_grant_id><funding_grant_id>U01 DK065193</funding_grant_id><pubmed_authors>Drug-Induced Liver Injury Network (DILIN)</pubmed_authors><pubmed_authors>Nicoletti P</pubmed_authors><pubmed_authors>Fontana RJ</pubmed_authors><pubmed_authors>Bjornsson ES</pubmed_authors><pubmed_authors>Chalasani N</pubmed_authors><pubmed_authors>Lucena MI</pubmed_authors><pubmed_authors>Li YJ</pubmed_authors><pubmed_authors>Stephens C</pubmed_authors><pubmed_authors>Aithal GP</pubmed_authors><pubmed_authors>Andrade RJ</pubmed_authors><pubmed_authors>International Drug-Induced Liver Injury Consortium (iDILIC)</pubmed_authors><pubmed_authors>Prospective European Drug-Induced Liver Injury (Pro-Euro DILI) Investigators</pubmed_authors><pubmed_authors>Govaere O</pubmed_authors><pubmed_authors>Watkins PB</pubmed_authors><pubmed_authors>Barnhart HX</pubmed_authors><pubmed_authors>Odin JA</pubmed_authors><pubmed_authors>Innocenti F</pubmed_authors><pubmed_authors>Daly AK</pubmed_authors><pubmed_authors>Etheridge AS</pubmed_authors><pubmed_authors>Dellinger A</pubmed_authors><pubmed_authors>Serrano J</pubmed_authors><pubmed_authors>Stolz A</pubmed_authors><pubmed_authors>Grove JI</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.</name><description>&lt;h4>Background &amp; aims&lt;/h4>Drug-induced liver injury (DILI) due to amoxicillin-clavulanate (AC) has been associated with HLA-A∗02:01, HLA-DRB1∗15:01, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC-DILI and to construct a genetic risk score (GRS).&lt;h4>Methods&lt;/h4>Transcriptome-wide association study and genome-wide association study analyses were performed on 444 AC-DILI cases and 10,397 population-based controls of European descent. Associations were confirmed in a validation cohort (n = 133 cases and 17,836 population-based controls). Discovery and validation AC-DILI cases were also compared with 1358 and 403 non-AC-DILI cases.&lt;h4>Results&lt;/h4>Transcriptome-wide association study revealed a significant association of AC-DILI risk </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Mar</publication><modification>2026-06-01T17:22:24.161Z</modification><creation>2025-04-04T20:40:38.055Z</creation></dates><accession>S-EPMC9974860</accession><cross_references><pubmed>36496055</pubmed><doi>10.1053/j.gastro.2022.11.036</doi></cross_references></HashMap>